Олинвацимаб

Rec. INN (наименование, зарегистрированное ВОЗ)

DB16265

2095504-49-5

immunoglobulin G1_V-lambda-C-kappa, anti-[Homo sapiens KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, VEGF-R2, FLK1, CD309)], monoclonal antibody;
gamma1 heavy chain (1-462) [N-terminal 6-mer (1-6) - VH (Homo sapiens IGHV1-3*01 (84.7%) -(IGHD) - IGHJ4*01 (100%)) [8.8.14] (7-127) -5-mer linker (128- 132) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (229) (133-230), hinge(231-245), CH2(246-355), CH3E12 (371), M14 (373) (356-460), CHS (461-462)) (133- 462)], (235-227')-disulfide with V-lambda-C-kappa light chain (1'-227') [N-terminal 5-mer (1'-5') -V-LAMBDA (Homo sapiens IGLV3-21*01 (81.2%) -IGLJ1*01 (100%)) [6.3.10] (6'-112') -8-mer linker(113'-120') -Homo sapiens IGKC*01 T1.3>S (122), Km3 A45.1 (166), V101 (204) (121'-227')]; dimer (241-241'':244-244'')-bisdisulfide

Поделиться этой страницей